SCHEMBL3230370

SCHEMBL3230370

CCCCN1CCC(CC(=O)Cc2cc(Cl)c(N)cc2OC)CC1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR4 Q13639 12/20 0.64
ACHE P22303 3/20 0.64
MEN1 O00255 1/20 0.64
ALDH1A1 P00352 1/20 0.64
CYP2D6 P10635 1/20 0.64
CYP2C9 P11712 1/20 0.64
TSHR P16473 1/20 0.64
KMT2A Q03164 1/20 0.64
DRD2 P14416 1/20 0.52
DRD4 P21917 1/20 0.52
CHRM4 P08173 1/20 0.51
CHRM5 P08912 1/20 0.51
ADRA2C P18825 1/20 0.51
CHRM3 P20309 1/20 0.51
HTR1D P28221 1/20 0.51
ADRA1B P35368 1/20 0.51
HTR2B P41595 1/20 0.51
HTR3A P46098 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8973729 0.99 HTR4 (0.63) HTR4ACHEMEN1ALDH1A1CYP2D6
SCHEMBL8971342 0.94 HTR4 (0.63) HTR4ACHEMEN1ALDH1A1CYP2D6
Hydrochloric Acid SCHEMBL8970748 0.93 HTR4 (0.62) HTR4ACHEMEN1ALDH1A1CYP2D6
SCHEMBL8970802 0.90 HTR4 (0.61) HTR4ACHEMEN1ALDH1A1CYP2D6
Hydrochloric Acid SCHEMBL8971667 0.89 HTR4 (0.60) HTR4ACHEMEN1ALDH1A1CYP2D6
Hydrochloric Acid SCHEMBL8971374 0.88 DRD2 (0.52) HTR4ACHEMEN1ALDH1A1CYP2D6
SCHEMBL8972034 0.88 HTR4 (0.53) HTR4ACHEMEN1ALDH1A1CYP2D6
SCHEMBL8971324 0.87 HTR4 (0.60) HTR4ACHEMEN1ALDH1A1CYP2D6
SCHEMBL8971587 0.87 DRD2 (0.52) HTR4ACHEMEN1ALDH1A1CYP2D6
Hydrochloric Acid SCHEMBL8971505 0.87 HTR4 (0.52) HTR4ACHEMEN1ALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020237096-A1 COMBINATION FOR LOWERING SERUM PHOSPHATE IN A PATIENT ARDELYX, INC. (US) 2020-11-26 WO disclosed
EP-3030252-A2 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT Ardelyx, Inc. (US) 2016-06-15 EP disclosed
WO-2015021358-A2 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT CHARMOT DOMINIQUE (US) 2015-02-12 WO disclosed
WO-2012170599-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION BRAINCELLS, INC. (US) 2012-12-13 WO disclosed
EP-2240445-A1 NOVEL SALT OF TEGASEROD Generics (UK) Limited (GB) 2010-10-20 EP disclosed
WO-2010099217-A1 MODULATION OF NEUROGENESIS USING D-CYCLOSERINE COMBINATIONS BRAINCELLS, INC. (US) 2010-09-02 WO disclosed
WO-2010015794-A1 NOVEL POLYMORPHIC FORMS OF TEGASEROD GENERICS [UK] LIMITED (GB) 2010-02-11 WO disclosed
EP-2125017-A2 MODULATION OF NEUROGENESIS WITH USE OF MODAFINIL Braincells, Inc. (US) 2009-12-02 EP disclosed
WO-2009141573-A1 NOVEL POLYMORPH OF TEGASEROD ADIPATE GENERICS [UK] LIMITED (GB) 2009-11-26 WO disclosed
WO-2009141571-A1 NOVEL POLYMORPH OF TEGASEROD HYDROCHLORIDE GENERICS [UK] LIMITED (GB) 2009-11-26 WO disclosed
EP-1853256-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2007-11-14 EP disclosed
WO-2007104035-A1 MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS BRAINCELLS, INC. (US) 2007-09-13 WO disclosed
WO-2007047978-A2 MODULATION OF NEUROGENESIS BY PDE INHIBITION BRAINCELLS, INC. (US) 2007-04-26 WO disclosed
WO-2007025177-A2 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION BRAINCELLS, INC. (US) 2007-03-01 WO disclosed
WO-2006083710-A2 USE OF 5-HT4 AGONIST FOR TREATING DELAYED GASTRIC EMPTYING WHICH MAY BE INDUCED BY A PROTON PUMP INHIBITOR NOVARTIS AG (CH) 2006-08-10 WO disclosed
EP-1385476-A4 METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS CEDARS SINAI MEDICAL CENTER (US) 2006-06-14 EP disclosed
EP-1385476-A2 METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS CEDARS-SINAI MEDICAL CENTER (US) 2004-02-04 EP disclosed
WO-2002083926-A2 METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS CEDARS-SINAI MEDICAL CENTER (US) 2002-10-24 WO disclosed
WO-2002038142-A2 SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2002-05-16 WO disclosed
EP-0700383-A1 NOVEL 1-PHENYLALKANONE 5-HT 4? RECEPTOR LIGANDS SYNTEX (U.S.A.) INC. (US) 1996-03-13 EP disclosed